Revance Therapeutics (RVNC) Misses Q1 EPS by 3c, provides outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
William Blair Reviews Revance Therapeutic (RVNC) EPS
May 13, 2024 7:04 AM EDTWilliam Blair analyst Tim Lugo reiterated an Outperform rating on Revance Therapeutic (NASDAQ: RVNC).
The analyst comments "Revance announced first quarter 2024 DAXXIFY revenues of $22.1 million, approximating our estimate of $22.2 million and just shy of consensus of $23.5 million. While the first quarter is typically... More
